Company intelligence / Profile preview

Oligo Medic

Ownership: Private
Development stage: Commercial

Overview

Oligo Medic’s lead product, JointRep™, has achieved CE mark approval and Health Canada approval. It has been used to treat over 7,000 patients across more than 20 countries. Clinical data show that a single treatment with JointRep™ provides clinically meaningful reduction (>90%) in knee pain and stiffness lasting at least two years compared to standard management of cartilage defects.

Therapeutic areas: Rheumatology
Modalities: Biomaterial-based medical device (specifically polyglucosamine hydrogel)Scaffold for tissue repairCarrier for biologics (potentially PRP, stem cells)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

JointRep

Commercial

Indications: Cartilage defects, Knee pain, Joint stiffness

Partnerships

Not explicitly listed; commercial network covers >30 countries suggesting distribution partnerships.

Beyond the preview

Go deeper on Oligo Medic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oligo Medic.

Explore the full profile